US 12,122,838 B2
Humanized anti-CCR7 receptor antibodies
Jaap Willem Back, Vleuten (NL); Ronald Boshuizen, Spanga (NL); Wouter Cornelis Puijk, Lelystad (NL); Johan Turkstra, Dronten (NL); and Klaus Heinrich Schwamborn, Nantes (FR)
Assigned to PepMab B.V., Lelystad (NL)
Filed by PepMab B.V., Lelystad (NL)
Filed on Jan. 18, 2022, as Appl. No. 17/577,493.
Application 17/577,493 is a division of application No. 16/813,780, filed on Mar. 10, 2020, granted, now 11,254,749.
Application 16/813,780 is a division of application No. 15/751,169, granted, now 10,640,565, issued on May 5, 2020, previously published as PCT/EP2016/069055, filed on Aug. 10, 2016.
Claims priority of application No. 15180415 (EP), filed on Aug. 10, 2015.
Prior Publication US 2022/0135693 A1, May 5, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01)
CPC C07K 16/2866 (2013.01) [A61K 39/39558 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/734 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01)] 9 Claims
 
1. A method for treating hepatic fibrosis, renal fibrosis, pulmonary fibrosis, skin fibrosis, cardiovascular fibrosis and/or gastrointestinal fibrosis, comprising administering a humanized anti- C-C chemokine receptor type 7 (anti-CCR7) antibody comprising the hypervariable regions HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2 and HVR-L3, wherein:
HVR-H1 comprises SEQ ID NO: 6;
HVR-H2 H1 comprises SEQ ID NO: 13;
HVR-H3 H1 comprises SEQ ID NO: 19;
HVR-L1 H1 comprises SEQ ID NO: 27;
HVR-L2 H1 comprises SEQ ID NO: 31; and
HVR-L3 H1 comprises SEQ ID NO: 36,
and wherein the antibody has at least one of:
a) a minimal affinity for a synthetic antigen with the amino acid sequence of SEQ ID NO: 76, wherein the minimal affinity is defined by a Kd that is not more than a 10× higher than the Kd of a mouse anti-CCR7 antibody of which the amino acid sequence of the heavy chain variable domain is SEQ ID NO: 1 and of which the amino acid sequence of the light chain variable domain is SEQ ID NO: 2; and,
b) an IC50 of no more than 100 nM for inhibiting CCR7-dependent intracellular signalling and/or CCR7 receptor internalization, by at least one CCR7-ligand selected from CCL19 and CCL21.